Drug Approval | June 02, 2026
Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma
The approval is supported by results from the Phase 3 SWOG 1826 trial
The approval is supported by results from the Phase 3 SWOG 1826 trial
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
Subscribe To Our Newsletter & Stay Updated
